News
02-12-2009, 04:20 AM
Researchers from Austria and Germany found that adding the bone drug zoledronic acid to endocrine therapy improved disease-free survival in premenopausal women with early stage breast cancer of the estrogen-responsive type.
More... (http://www.medicalnewstoday.com/articles/138713.php)
More... (http://www.medicalnewstoday.com/articles/138713.php)